Any prior treatment with any investigational drug within the preceding  weeks
Use of an investigational agent or an investigational device within  days before administration of first dose of study drug(s).
Use of any investigational drug within the past  weeks
Prior treatment with any investigational drug within the preceding  weeks
Subjects currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug
Use of an investigational agent or an investigational device within  days before administration of first dose of study drug(s).
Prior treatment with any investigational drug within the preceding  weeks
Patients must not have received an investigational drug within  days
Participants may not be receiving treatment with any investigational drug or biologic within  days of randomization or at any time during the study.
Use of an investigational small molecule drug during the  days prior to screening or use of an investigational oligonucleotide or biologic drug during the prior  days
Patients who have received treatment with an investigational drug within  days preceding the first dose of study medication
Treatment within  days prior to randomization with another investigational device or drug study (ies).
Have received prior treatment with any investigational drug within  weeks prior to dose assignment
The patient has received an investigational drug within  days of the first dose of study drug.
Patient has received an investigational drug within  days of enrollment
Any other investigational drug within  days prior to registration and during the study
Prior treatment with any investigational drug within the preceding  weeks
Has received an investigational therapy within  days of first dose of study drug
Has received treatment with any investigational drug in the previous  weeks
The patient has received any investigational drug within the past  weeks
Treatment with any investigational drug within  days prior to registration.
Taken an investigational drug within  weeks prior to study drug administration or plans to take an investigational agent during the study
Investigational drug use within  days of CD
Any investigational drug within  days prior to study treatment.
Rx with an investigational drug w/in  month of infusion, other than for treatment of their underlying disease
Patient is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug
Use of any investigational drug within  days prior to the first dose of study drug
Have received treatment within  days of the initial dose of olaratumab with an investigational product or non-approved use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
The use of another investigational drug within the previous  days
No investigational therapy within four weeks of the first dose of study drug.
Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within  days or  half lives before enrollment or is currently enrolled in the treatment stage of an investigational study
Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within  months of enrollment
Patients who have received treatment with an investigational drug within  days preceding the first dose of study medication
Currently receiving treatment with another investigational device or drug study, or <  days since ending treatment with another investigational device or drug study(s); other investigational procedures while participating in this study are excluded
Use of other investigational drug within  days of enrollment.
Currently receiving treatment in another investigational device or drug study, or less than  days between ending treatment on another investigational device or drug study(ies) and start of IP treatment. Other investigational procedures while participating in this study are excluded.
Recipient must not have received any investigational drug within  days of starting conditioning treatment
Currently enrolled in another clinical study or used any investigational drug or device within  days (or  x half-life for investigational drugs where the half-life is known) preceding informed consent
Received an investigational drug within  days of starting treatment, or have not recovered from side effects of an investigational drug
Patients receiving an investigational drug within  days prior to registration
Currently receiving treatment in another investigational device or drug study, or less than  days since ending treatment on another investigational device or drug study(s)
Currently receiving any investigational drug or device in another clinical trial or within  days preceding informed consent.
Use of any investigational product (IP) or investigational medical device within  days before day  of study drug
Received any investigational compound within  days prior to the first dose of study drug or planned during the treatment period or follow-up
Participation in any investigational drug study within  days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Patient is simultaneously participating in another investigational drug or device study
Investigational agent received within  days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade  or less prior to first dose of study drug
Enrollment in any other investigational treatment study or use of an investigational agent, or has not yet completed at least  half-lives since ending another investigational device or drug trial
Any investigational drug within  weeks
Subjects who participated in an investigational drug or device study within  days prior to study entry
Prior treatment with any investigational drug within the preceding  weeks
Concurrent enrollment in any other study using an investigational drug
Received an investigational drug, was vaccinated with live attenuated vaccines, or used an invasive investigational medical device within  weeks before the planned first dose of study drug, or is currently being treated in an investigational study
Planned treatment, or treatment with any investigational drug within  weeks prior to screening.
Received an investigational product or been treated with an investigational device within  days prior to first drug administration, or plans to start any other investigational product or device study within  days after last drug administration.
Patient on other investigational drug
No investigational therapy within  weeks of first dose of study drug
Treatment with any investigational drug within  days prior to initiating study medications
Patients participating in an investigational new drug protocol within  days before enrollment.
Patient has participated in a prior investigational study within  weeks prior to initiating study drug.
Patient who has participated in a prior investigational study within  days prior to enrollment
Treated with any investigational drug within  weeks of the first dose of study treatment.
Prior therapy with TEW- or received any investigational drug within the prior  days
Treatment with any investigational drug within  days prior to registration.
Prior treatment with any investigational drug within the preceding  weeks prior to starting study drug
Patient is currently participating or has participated in a study with an investigational compound or devise within  days of initial dosing with study drug(s)
Any investigational drug <  weeks prior to the first dose of study drug or not recovered from effects of prior investigational agent
Use of any other investigational drug
Treatment with another investigational drug (with the exception of anticancer immune therapy) or device, or approved therapy for investigational use, within  times the half-life of the drug or within  weeks prior to study day  if the half life is not known.
Subject participating in any other study involving an investigational (unapproved) drug or device within the past  days.
Subject is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.
Use of any investigational drug within  days prior to the first dose of study drug
Participated in any other study in which receipt of an investigational new drug or investigational device occurred within  days of first dose of study drug
Currently receiving treatment in another investigational device or drug study, or less than  days since ending treatment on another investigational device or drug study
Treatment with any investigational drug within  days before randomisation.
Prior treatments usage as defined: A) Use of an investigational anti-cancer drug within  days or  half-lives, whichever is longer, prior to the first dose of the investigational products:; B) A minimum of  days between termination of the investigational drug and administration of GSK; C) Any therapy related toxicities must also have resolved to Grade  or less. Note that an investigational drug is defined as a drug without an approved oncologic indication; D) Chemotherapy, radiotherapy, anti-neoplastic antibody or targeted therapy or immunotherapy within  days, major surgery within  days (or  days for prior nitrosoureas or mitomycin C) prior to the first dose of the investigational product. Anti-androgen (e.g., bicalutamide) therapies for prostate cancer must be stopped  weeks prior to enrollment. Second line hormone therapies such as enzalutamide, abiraterone, or orteronel should be stopped  weeks prior to enrollment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone (up to  mg/day) and still be eligible for this study.
Currently receiving treatment in another investigational device or drug study or less than  days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
Investigational drug within  days of first trilaciclib (GT) dose
Are currently enrolled in another clinical study or used any investigational drug or device within  days (or  x the half-life of the investigational drug/device, whichever is longer) preceding informed consent
Another investigational drug
Patients participating in an investigational new drug protocol within  days before enrollment
Participant has received an investigational drug or used an invasive investigational medical device within  days prior to Study Entry or is currently enrolled in an investigational study
Received other cancer treatment or investigational drug within  weeks prior to screening
Patient who has participated in a prior therapeutic investigational drug study within  days prior to enrollment
Patient has received an investigational agent or used an investigational device within  days of the first dose of study drug
Patients must not have prior treatment with any investigational drug within the preceding  days and must not be planning to receive any other investigational drug for the duration of the study
Participation in any investigational drug study within  days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Received ibrutinib or following therapies considered investigational for treatment of cGVHD including imatinib, bortezomib, ruxolitnib, or entospletinib, within  wks prior to starting AMG  or is currently receiving treatment in another investigational drug or device study.
Use of an investigational anti-cancer drug within  days preceding the first dose of dabrafenib
Prior treatment with any investigational drug within the preceding  weeks
Patients who have not yet completed at least  days ( days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments
Prior treatment with any investigational drug within the preceding  weeks
Individuals who have received any investigational drug within  weeks
Currently participating or enrolled in another investigational treatment, device or drug study through follow up
Are currently enrolled in, or discontinued within the last  days from a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Treatment with systemic investigational drug within  weeks or topical investigational drug within  days of study start
Subjects who participated in any other investigational drug trial or had exposure to any other investigational agent, device or procedure < weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for CMV post allogeneic HCT.
Subject currently is enrolled in or has not yet completed at least  days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s)
Investigational drug other than NEOD within  weeks
Use of an investigational drug within  days prior to screening.
Use of any investigational drug within  weeks
No investigational drug within  weeks of starting study treatment.
Investigational agent received within  days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade  or less prior to first dose of study drug
French subjects: the French subject has participated in any study using an investigational drug during the previous  days
Use of any investigational drug or treatment within  weeks prior to enrollment
Chemotherapy or investigational drug therapy for cancer up to  days prior to day- of study.
Participation in any other investigational trial in which receipt of investigational drug or device occurred within  days prior to screening for this study
Current enrollment in another interventional clinical study or used any investigational drug or device within the past  days preceding informed consent.
Participation in any investigational drug study within  days prior to ISF administration; (subject must have recovered from all acute effects of previously administered investigational agents)
Participant who were treated with other investigational drug or medical device within  weeks prior to the planned first day of study drug dosing.
Treatment with any investigational drug within  weeks of first dose of mirvetuximab soravtansine
Have received treatment within  days of the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
investigational drug within  days
investigational drug within the  days prior to planned first dose of study drug, or
Any other investigational drug/medical device within  weeks prior to the first dose
Participating in another investigational drug or device trial that has not completed the follow-up period
Treatment with another investigational drug or device within  days prior to Day 
Currently enrolled in another investigational device or drug study
Treatment with an investigational drug within  weeks prior to the first dose of study drug
Prior treatment with any investigational drug within the preceding  weeks
Use of investigational drug within  weeks of Day  Week  or current enrollment in an investigational drug or device study
Investigational drug use within  days of the first dose of PLX
Subject is currently enrolled in or has not yet completed at least  days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.
Prior treatment with any investigational drug within the preceding  weeks
Subject currently is enrolled in or has not yet completed at least  days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)
Patients who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within  days or  half -lives before registration or is currently enrolled in the treatment stage of an investigational study are not eligible; please contact PI for further details on wash-out period and eligibility of such patients
Treatment within the last  days with any investigational drug
Participating in any other investigational study for either drug or device which could influence collection of valid data under this study
Use of an investigational drug within  month prior to dosing
Patients who have received an investigational agent or have used an investigational device within  weeks of the first dose of study drug
Currently enrolled in another interventional clinical study or used any investigational drug or device within the past  days preceding informed consent
Enrollment in another investigational drug trial
Prior treatment with any investigational drug or device within  days prior to Randomization (within  weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;
Subject has participated in an investigational drug or device research study within  days of enrollment that would interfere with this study.
Participating in another investigational drug or device study in which patient has not completed the follow-up phase for the primary endpoint at least  days prior to enrollment
Any investigational drug being administered during the study
Treatment with any investigational drug or investigational biologic within  days of initiating study treatment or during the study
Treatment with any investigational drug or investigational biologic within  days of initiating study treatment or during the study
Patient aged <  years who received any investigational drug (defined as a medication with no marketing authorization granted for any age class and any indication) within  days prior to Day , or patient aged  years who received any investigational drug within  days prior to Day  or is expected to receive investigational drugs prior to study completion.
Patients who have received an investigational drug within  days of enrollment in study
Enrollment on an interventional investigational study
Use of an investigational drug in the  months prior to screening and must agree to not participate in any drug or device study while enrolled in this study
Patients who are participating in another experimental protocol during the study period (last intake of investigational drug within  months prior to first study drug injection)
Have received any investigational new drug within the past  days or planning to receive such during the study period
Has ever participated in a previous study of aprepitant or fosaprepitant or has taken an investigational drug with the last  weeks.
Has participated in a study with an unapproved investigational compound (monoclonal antibodies are excepted) or device within  days of the first dose of study drug
The patient has participated in another investigational drug study within  days of scheduled surgery
Received an investigational drug within  days prior to first dose of panitumumab-IRDye
Received an investigational drug within  days prior to first dose of panitumumab-IRDye
Treatment with another investigational drug or other intervention with  hours of injection
Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within  days prior to study radiotracer administration
Treatment with any investigational drug, device or biologic agent within  days prior to administration of [F]-ML-.
Received an investigational drug within  days prior to first dose of panitumumab IRDye
Received an investigational drug within  days prior to first dose of cetuximab IRDye
Received an investigational drug within  days prior to first dose of cetuximab-IRDye
Received investigational therapy with another drug or biologic within  days prior to the start of CMP- dosing on WD. However, if an investigational drug has a short half-life, a shorter wash out period may be acceptable upon permission given by the Sponsor.
Investigational drug use within  days of the first dose of avelumab
Currently receiving treatment in another investigational device or drug study, or less than  days since ending treatment on another investigational device or drug study.
Received an investigational drug within  days prior to first dose of cetuximab IRDye
The subject has participated in another investigational drug study within  days of scheduled surgery.
Patient is participating in any other investigational drug or device study
Have received treatment within  days prior to the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Have taken an investigational drug within  days of enrollment.
The patient has received an investigational drug within  days of the first dose of study drug.
Subjects who have taken an investigational drug within  days of enrollment.
Subjects who have taken an investigational drug within  days of enrollment.
Use of an investigational drug within  days prior to the first dose of study drug. Note that to be eligible, any drug-related toxicity should have recovered to Grade  or less, with the exception of alopecia.
Currently receiving treatment in another investigational device or drug study, or less than  days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
